Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study

Figure 5

The proportional breakdown of costs of screening and treatment for selected strategies. A. Once-lifetime screening with VIA/VILI at age 35 years; B. Once-lifetime screening with careHPV@0.5 pg/ml at age 35 years; C. Routine screening with VIA/VILI at IARC-recommended intervals; D. Routine screening with careHPV@0.5 pg/ml at IARC-recommended intervals. The greatest component of the total lifetime cost is the cancer treatment cost for once-lifetime screening strategies. In contrast, for screening according to the IARC-recommended intervals (the most intensive regular screening strategy examined) the screening test costs dominate.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us